Julie Schwartzbard
Neurology · Aventura, FLNPI 1578558821
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $279,957 of the $443,652 with a category attached, or 63.1%. 51 manufacturers reported payments, led by Lilly USA, LLC at 29.8% of the total. Reporting peaked in 2023 at $86,474 and has fallen 71.3% since, to $24,829 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,049 payments — averaging $422.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$132K
- Eisai Inc.$111K
- Acorda Therapeutics, Inc$44K
- AbbVie$31K
- Neurocrine Biosciences, Inc.$26K
- Avanir Pharmaceuticals, Inc.$21K
- plus $78K from 45 others
Across 535 payments — averaging $25,232 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8.8M
- AbbVie$3.1M
- UCB SA$451K
- Eisai Inc.$382K
- Amneal Pharmaceuticals LLC$371K
- Roche TCRC, Inc.$204K
- plus $194K from 7 others
What the payments were for
- Consulting fees$104,19723%
- Speaking & faculty fees$279,95763%
- Grants$850%
- Travel & lodging$39,2439%
- Food & beverage$18,2694%
- Education$1,9020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$443,652 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 17 | $83,007 |
| RytaryCarbidopa/Levodopa | 18 | $36,019 |
| Emgality PenGalcanezumab-Gnlm | 18 | $15,897 |
| Memantine Hcl ErMemantine Hcl | 14 | $2,271 |
| Carbamazepine ErCarbamazepine | 14 | $674 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 22 | $658 |
| Lamotrigine | 11 | $476 |
| Duloxetine Hcl | 12 | $440 |
| Donepezil Hcl | 23 | $352 |
| Gabapentin | 16 | $318 |
| Quetiapine Fumarate | 19 | $304 |
| Amitriptyline Hcl | 11 | $303 |
| Trazodone Hcl | 16 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $2,166 | $83,00717 claims |
| Amneal Pharmaceuticals LLCRytary | $19,534 | $36,01918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Aventura
- Jeffrey GelblumAventura$324K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.